专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2007010013A3 COMBINATION COMPRISING A PYRIMIDYLAMINOBENZAMIDES AND A FLT-3 INHIBITOR FOR TREATING PROLIFERATIVE DISEASES 审中-公开
标题翻译：包含吡嗪基胺苯甲酸和用于治疗增殖性疾病的FLT-3抑制剂的组合
公开(公告)号：WO2007010013A3
公开(公告)日：2007-05-03
申请号：PCT/EP2006064430
申请日：2006-07-19
申请人： NOVARTIS AG , NOVARTIS PHARMA GMBH , MANLEY PAUL W , ROESEL JOHANNES
发明人： MANLEY PAUL W , ROESEL JOHANNES
IPC分类号： A61K31/506 , A61P35/00
CPC分类号： A61K45/06 , A61K31/506 , A61K2300/00
摘要： The invention provides a pharmaceutical combination comprising: a) a pyrimidylaminobenzamide compound; and b) a Flt-3inhibitor, and a method for treating or preventing a proliferative disease using such a combination.
摘要翻译：本发明提供药物组合，其包含：a）嘧啶基氨基苯甲酰胺化合物; 和b）Flt-3抑制剂，以及使用这种组合治疗或预防增殖性疾病的方法。

2. 发明申请

WO2007022042A2 ORGANIC COMPOUNDS 审中-公开
标题翻译：有机化合物
公开(公告)号：WO2007022042A2
公开(公告)日：2007-02-22
申请号：PCT/US2006031561
申请日：2006-08-10
申请人： NOVARTIS AG , NOVARTIS PHARMA GMBH , MANLEY PAUL W , BHALLA KAPIL N
发明人： MANLEY PAUL W , BHALLA KAPIL N
CPC分类号： A61K31/506 , A61K31/365 , A61K31/395 , A61K31/416 , A61K31/4184 , A61K45/06 , A61K2300/00
摘要： The invention provides a pharmaceutical combination comprising: a) a pyrimidylaminobenzamide compound; and b) an HSP90 inhibitor, and a method for treating or preventing a proliferative disease using such a combination.
摘要翻译：本发明提供药物组合，其包含：a）嘧啶基氨基苯甲酰胺化合物; 和b）HSP90抑制剂，以及使用这种组合治疗或预防增殖性疾病的方法。

3. 发明申请

WO2007010012A2 COMBINATION OF ORGANIC COMPOUNDS 审中-公开
标题翻译：有机化合物的组合
公开(公告)号：WO2007010012A2
公开(公告)日：2007-01-25
申请号：PCT/EP2006064429
申请日：2006-07-19
申请人： NOVARTIS AG , NOVARTIS PHARMA GMBH , MANLEY PAUL W , LANE HEIDI
发明人： MANLEY PAUL W , LANE HEIDI
IPC分类号： A61K31/506 , A61K31/436 , A61P35/00
CPC分类号： A61K45/06 , A61K31/436 , A61K31/506 , A61K2300/00
摘要： The invention provides a pharmaceutical combination comprising: a) a pyrimidylaminobenzamide compound, and b) an mTOR kinase inhibitor and a method for treating or preventing a proliferative disease using such a combination.
摘要翻译：本发明提供药物组合，其包含：a）嘧啶氨基苯甲酰胺化合物，和b）mTOR激酶抑制剂和使用这种组合治疗或预防增殖性疾病的方法。

4. 发明申请

WO2007115289A3 COMBINATIONS COMPRISING BCR-ABL/C-KIT/PDGF-R TK INHIBITORS FOR TREATING CANCER 审中-公开
标题翻译：包含BCR-ABL / C-KIT / PDGF-R TK抑制剂治疗癌症的组合
公开(公告)号：WO2007115289A3
公开(公告)日：2008-04-10
申请号：PCT/US2007065916
申请日：2007-04-04
申请人： NOVARTIS AG , NOVARTIS PHARMA GMBH , BURKE GREGORY PETER , LINNARTZ RONALD RICHARD , MANLEY PAUL W , VERSACE RICHARD WILLIAM
发明人： BURKE GREGORY PETER , LINNARTZ RONALD RICHARD , MANLEY PAUL W , VERSACE RICHARD WILLIAM
IPC分类号： A61K31/454 , A61K31/4709 , A61K31/473 , A61K31/506 , A61K31/553 , A61K31/573 , A61K31/704 , A61K45/06 , A61P35/00 , A61P35/04
CPC分类号： A61K45/06 , A61K31/454 , A61K31/4709 , A61K31/473 , A61K31/506 , A61K31/553 , A61K31/573 , A61K31/704 , A61K2300/00
摘要： The invention relates to a combination comprising a Bcr-Abl, c-Kit and PDGF-R tyrosine kinase inhibitor; and one or more pharmaceutically active agents; pharmaceutical compositions comprising said combination; methods of treatment comprising said combination; processes for making said combination; and a commercial package comprising said combination.
摘要翻译：本发明涉及包含Bcr-Abl，c-Kit和PDGF-R酪氨酸激酶抑制剂的组合; 和一种或多种药物活性剂; 包含所述组合的药物组合物; 包括所述组合的治疗方法; 制作所述组合的方法; 以及包括所述组合的商业包装。

5. 发明申请

WO2006056399A3 COMBINATIONS OF JAK INHIBITORS AND AT LEAST ONE OF BCR-ABL, FLT-3, FAK OR RAF KINASE INHIBITORS 审中-公开
标题翻译： JAK抑制剂和至少一种BCR-ABL，FLT-3，FAK或RAF激酶抑制剂的组合
公开(公告)号：WO2006056399A3
公开(公告)日：2006-08-31
申请号：PCT/EP2005012480
申请日：2005-11-22
申请人： NOVARTIS AG , NOVARTIS PHARMA GMBH , COOKE NIGEL GRAHAM , MANLEY PAUL W
发明人： COOKE NIGEL GRAHAM , MANLEY PAUL W
IPC分类号： A61K31/277 , A61K31/4025 , A61K31/517 , A61K31/519 , A61P35/02
CPC分类号： A61K31/5377 , A61K31/277 , A61K31/4025 , A61K31/506 , A61K31/517 , A61K31/519 , A61K45/06 , A61K2300/00
摘要： The invention provides a pharmaceutical combination comprising: a) at least one agent selected from Bcr-Abl, Flt-3, FAK and RAF kinase inhibitors; and b) at least one JAK kinase inhibitor and a method for treating or preventing a proliferative disease using such a combination.
摘要翻译：本发明提供药物组合，其包含：a）至少一种选自Bcr-Abl，Flt-3，FAK和RAF激酶抑制剂的药剂; 和b）至少一种JAK激酶抑制剂和使用这种组合治疗或预防增殖性疾病的方法。

6. 发明申请

WO2007116025A3 USE OF C-SRC INHIBITORS IN COMBINATION WITH A PYRIMIDYLAMINOBENZAMIDE COMPOUND FOR THE TREATMENT OF LEUKEMIA 审中-公开
标题翻译： C-SRC抑制剂与吡嗪酰胺苯甲酸化合物联合用于治疗白血病的用途
公开(公告)号：WO2007116025A3
公开(公告)日：2007-12-13
申请号：PCT/EP2007053399
申请日：2007-04-05
申请人： NOVARTIS AG , NOVARTIS PHARMA GMBH , MANLEY PAUL W
发明人： MANLEY PAUL W
IPC分类号： A61K31/506 , A61K31/4709 , A61K31/519 , A61P35/02
CPC分类号： A61K31/4709 , A61K31/506 , A61K31/519
摘要： The invention relates to a combination which comprises (a) at least one compound decreasing the c-Src activity and (b) a pyrimidylaminobenzamide compound; to pharmaceutical compositions comprising said combinations; and to a method of treating a warm-blooded animal having leukemia, especially chronic myelogenous leukemia, comprising administering to the animal at least one compound inhibiting the activity of a member of the Src kinase family, the Btk kinase family, the Tec kinase family or a Raf kinase inhibitor, in particular inhibiting the c-Src protein tyrosine kinase activity or inhibiting simultaneously the c-Src protein tyrosine kinase activity and the Bcr-Abl tyrosine kinase activity, in combination with a pyrimidylaminobenzamide compound, in particular 4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazol-1-yl)-3- (trifluoromethyl)phenyl] benzamide.
摘要翻译：本发明涉及一种组合，其包含（a）至少一种降低c-Src活性的化合物和（b）嘧啶基氨基苯甲酰胺化合物; 包含所述组合的药物组合物; 以及治疗具有白血病，特别是慢性骨髓性白血病的温血动物的方法，包括向所述动物施用至少一种抑制Src激酶家族成员，Btk激酶家族，Tec激酶家族的活性的化合物或 Raf激酶抑制剂，特别是抑制c-Src蛋白酪氨酸激酶活性或同时抑制c-Src蛋白酪氨酸激酶活性和Bcr-Abl酪氨酸激酶活性，与嘧啶氨基苯甲酰胺化合物，特别是4-甲基-3 - [[4-（3-吡啶基）-2-嘧啶基]氨基] -N- [5-（4-甲基-1H-咪唑-1-基）-3-（三氟甲基）苯基]苯甲酰胺。

7. 发明申请

WO2006079539A3 USE OF PYRIMIDYLAMINOBENZAMIDES FOR THE TREATMENT OF DISEASES THAT RESPOND TO MODULATION OF TIE-2 KINASE ACTIVITY 审中-公开
标题翻译：用于治疗针对TIE-2激酶活性调节的疾病的吡咯烷亚胺苯甲酸酯的应用
公开(公告)号：WO2006079539A3
公开(公告)日：2007-11-29
申请号：PCT/EP2006000686
申请日：2006-01-26
申请人： NOVARTIS AG , NOVARTIS PHARMA GMBH , MANLEY PAUL W , MARTINY-BARON GEORG , MESTAN JUERGEN
发明人： MANLEY PAUL W , MARTINY-BARON GEORG , MESTAN JUERGEN
IPC分类号： A61K31/506 , A61P9/12 , A61P35/00
CPC分类号： A61K31/506
摘要： The present invention relates to the use of pyrimidylaminobenzamide compounds for the preparation of a drug for the treatment of diseases that respond to modulation of kinase, especially tie-2 kinase, activity, especially for the curative and/or prophylactic treatment of leukemia, myelodysplastic syndromes or pulmonary hypertension, and to a method of treating diseases that respond to modulation of kinase activity, especially tie-2 kinase activity.
摘要翻译：本发明涉及嘧啶氨基苯甲酰胺化合物在制备用于治疗对激酶调节，特别是tie-2激酶，特别是用于治疗和/或预防性治疗白血病，骨髓增生异常综合征的活性的疾病的药物中的用途或肺动脉高压，以及治疗对激酶活性调节，特别是tie-2激酶活性作出反应的疾病的方法。

8. 发明申请

WO2007071393A3 SULPHONAMIDOANILINE DERIVATIVES BEING JANUS KINASES INHIBITORS 审中-公开
标题翻译：磺胺类药物抑制剂磺酰胺衍生物
公开(公告)号：WO2007071393A3
公开(公告)日：2007-07-26
申请号：PCT/EP2006012311
申请日：2006-12-20
申请人： NOVARTIS AG , NOVARTIS PHARMA GMBH , CAPRARO HANS-GEORG , COUPEZ BERNARD , FURET PASCAL , MANLEY PAUL W , PISSOT SOLDERMANN CAROLE
发明人： CAPRARO HANS-GEORG , COUPEZ BERNARD , FURET PASCAL , MANLEY PAUL W , PISSOT SOLDERMANN CAROLE
IPC分类号： C07D473/16 , A61K31/52 , A61K31/5377 , A61P35/00 , C07D473/18 , C07D487/04 , C07D519/00
CPC分类号： C07D473/16 , C07D473/18 , C07D487/04 , C07D519/00
摘要： The invention relates to sulphonamidoanilines of formula (I) wherein A is N or CH, W, X, Y and Z are N or CH under the proviso that at least one of the three symbols W, X and Y represent CH, R 1 represents NR 4 R 5 or OR 4 , wherein R 4 represents optionally substituted alkyl, optionally substituted cycloalkyl optionally comprising one or two nitrogen or oxygen atoms, or substituted aryl, and R 5 represents hydrogen or unsubstituted or substituted alkyl, or R 4 and R 5 together with the nitrogen to which they are attached represent an optionally substituted five- or six-membered nitrogen containing monocyclic ring, an optionally substituted nitrogen containing fully saturated bicyclic ring, or an spirocyclic fully saturated ring system containing one or two nitrogen atoms, R 2 is hydrogen, lower alkenyl or alkyl, R 3 is alkyl which is unsubstituted or mono-, di- or trisubstituted by halogen; alkenyl or aryl, and their salts; processes for their preparation, their application in the treatment of the human or animal body, the use thereof - alone or in combination with one or more other pharmaceutically active compounds - for the treatment of diseases, a method for the treatment of such a disease and the use of such a compound - alone or in combination with one or more other pharmaceutically active compounds - for the manufacture of a pharmaceutical preparation for the treatment of a proliferative disease.
摘要翻译：本发明涉及式（I）的磺酰氨基苯胺，其中A为N或CH，W，X，Y和Z为N或CH，条件是三个符号W，X和Y中的至少一个表示CH，R < > 1表示NR 4 R 5或OR 4，其中R 4表示任选取代的烷基任选包含一个或两个氮原子或氧原子的任选取代的环烷基或取代的芳基，R 5表示氢或未取代或取代的烷基，或R 4和R 3 > 5个与它们所连接的氮一起代表任选取代的五元或六元含氮单环，任选取代的含氮完全饱和双环，或含有一个或多个两个氮原子，R 2是氢，低级烯基或烷基，R 3是未被取代的或被卤代基单 - ，二 - 或三取代的烷基 N; 烯基或芳基，及其盐; 其制备方法，它们在人体或动物体内的治疗中的应用，其单独或与一种或多种其它药物活性化合物组合用于治疗疾病的用途，治疗这种疾病的方法和使用这种化合物 - 单独或与一种或多种其它药学活性化合物组合用于制备用于治疗增殖性疾病的药物制剂。

9. 发明申请

WO2006059234A3 BICYCLIC AMIDES AS KINASE INHIBITORS 审中-公开
标题翻译：作为激酶抑制剂的双环酰胺
公开(公告)号：WO2006059234A3
公开(公告)日：2006-07-20
申请号：PCT/IB2005004030
申请日：2005-09-14
申请人： NOVARTIS AG , NOVARTIS PHARMA GMBH , BOLD GUIDO , CAPRARO HANS-GEORG , CARAVATTI GIORGIO , FLOERSHEIMER ANDREAS , FURET PASCAL , MANLEY PAUL W , VAUPEL ANDREA , PISSOT SOLDERMANN CAROLE , GESSIER FRANCOIS , SCHNELL CHRISTIAN , LITTLEWOOD-EVANS AMANDA JANE , KAPA PRASAD KOTESWARA , BAJWA JOGINDER S , JIANG XINGLONG
发明人： BOLD GUIDO , CAPRARO HANS-GEORG , CARAVATTI GIORGIO , FLOERSHEIMER ANDREAS , FURET PASCAL , MANLEY PAUL W , VAUPEL ANDREA , PISSOT SOLDERMANN CAROLE , GESSIER FRANCOIS , SCHNELL CHRISTIAN , LITTLEWOOD-EVANS AMANDA JANE , KAPA PRASAD KOTESWARA , BAJWA JOGINDER S , JIANG XINGLONG
IPC分类号： C07D403/12 , A61K31/505 , C07D239/46 , C07D413/12
CPC分类号： C07D239/47 , C07D403/12 , C07D413/12
摘要： The invention relates to compounds of formula (I) and their use in the treatment of the animal or human body, to pharmaceutical compositions comprising a compound of formula I and to the use of a compound of formula I for the preparation of pharmaceutical compositions for use in the treatment of protein kinase dependent diseases, especially of proliferative diseases, such as in particular tumour diseases.
摘要翻译：本发明涉及式（I）化合物及其在治疗动物或人体中的用途，涉及包含式I化合物的药物组合物，以及涉及式I化合物在制备使用的药物组合物中的用途用于治疗蛋白激酶依赖性疾病，特别是增殖性疾病，例如特别是肿瘤疾病。

10. 发明申请

WO2007115289A8 COMBINATIONS COMPRISING BCR-ABL/C-KIT/PDGF-R TK INHIBITORS FOR TREATING CANCER 审中-公开
标题翻译：包含BCR-ABL / C-KIT / PDGF-R TK抑制剂的组合用于治疗癌症
公开(公告)号：WO2007115289A8
公开(公告)日：2008-10-16
申请号：PCT/US2007065916
申请日：2007-04-04
申请人： NOVARTIS AG , NOVARTIS PHARMA GMBH , BURKE GREGORY PETER , LINNARTZ RONALD RICHARD , MANLEY PAUL W , VERSACE RICHARD WILLIAM
发明人： BURKE GREGORY PETER , LINNARTZ RONALD RICHARD , MANLEY PAUL W , VERSACE RICHARD WILLIAM
IPC分类号： A61K31/454 , A61K31/4709 , A61K31/473 , A61K31/506 , A61K31/553 , A61K31/573 , A61K31/704 , A61K45/06 , A61P35/00 , A61P35/04
CPC分类号： A61K45/06 , A61K31/454 , A61K31/4709 , A61K31/473 , A61K31/506 , A61K31/553 , A61K31/573 , A61K31/704 , A61K2300/00
摘要： The invention relates to a combination comprising a Bcr-Abl, c-Kit and PDGF-R tyrosine kinase inhibitor; and one or more pharmaceutically active agents; pharmaceutical compositions comprising said combination; methods of treatment comprising said combination; processes for making said combination; and a commercial package comprising said combination.
摘要翻译：本发明涉及包含Bcr-Abl，c-Kit和PDGF-R酪氨酸激酶抑制剂的组合; 和一种或多种药物活性剂; 包含所述组合的药物组合物包含所述组合的治疗方法; 制造所述组合的过程; 和包含所述组合的商业包装。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式